We are excited to attend the 5th In Vivo Cell Engineering and Gene Editing Summit from July 28th - 30th in Boston, MA. Fueled by more than $7.3 billion in recent pharmaceutical investments, in vivo cell engineering and gene editing have reached a pivotal stage of growth. As a global leader in gene editing services, Biocytogen utilizes cutting-edge technology to provide best-in-class products and support. Come visit our booth to learn more about how we can advance your research studies.
What is the 5th In Vivo Engineering and Gene Editing Summit?
The 5th In Vivo Engineering and Gene Editing Summit is where leading researchers and translational leaders come together to discuss the drivers of in vivo innovation and ex vivo transitions. Across three days, attendees will explore case studies, share expert insights, and have collaborative discussions addressing the latest scientific and development challenges. This is an essential event for developers to refine their approaches and strengthen their strategies moving forward.
Event Overview
Date: July 28th - 30th, 2026
Venue: Hotel Commonwealth, 500 Commonwealth Avenue Boston, MA 02215
Event Schedule
For more information, please refer to the event agenda.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen has established a dual-engine platform combining a fully human antibody library with an extensive target-humanized mouse model portfolio, enabling a systematic approach to accelerating global drug discovery and development.
Biocytogen has independently developed its proprietary RenMice® (RenMab®/RenLite®/RenNano®/RenTCR™/RenTCR mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, hu-VHH discovery, and TCR mimic antibody discovery, and has established a sub-brand, RenSuper™ Biologics, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2025, more than 350 agreements for therapeutic antibodies and clinical assets—spanning co-development, out-licensing, and transfers—have been established globally, including landmark partnerships with leading multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen, Jiangsu, Shanghai), the USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
